GMED — Globus Medical Cashflow Statement
0.000.00%
- $10.01bn
- $9.57bn
- $2.52bn
- 96
- 30
- 90
- 84
Annual cashflow statement for Globus Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 102 | 149 | 190 | 123 | 103 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 75.6 | 92.1 | 47.5 | 150 | 387 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -37.6 | -17.3 | -105 | -117 | -97.6 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Cash from Operating Activities | 199 | 276 | 178 | 243 | 521 |
Capital Expenditures | -63.7 | -56.9 | -74 | -78.3 | -115 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -53.7 | -319 | -36.3 | 381 | -60.6 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -117 | -376 | -110 | 303 | -176 |
Financing Cash Flow Items | -6.32 | -9.35 | -7.18 | -18.7 | -52.3 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | -38.7 | 54.1 | -110 | -232 | -27.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 43.7 | -46.3 | -42.6 | 317 | 317 |